Sirius Medical raised € 4.4 million for the commercial introduction of Sirius Pintuition and for the development of additional products. The Series A financing was raised by a group of investors led by BOM Brabant Ventures. Co-investors are Curie Capital and Holland Capital; additional funding came from NWO, Stichting Mibiton, business angels, Sirius’ own management, and existing shareholders.
Hubert Martens, CEO of Sirius Medical Systems, expects that this will enable Sirius Medical to execute its ambitious growth plans: “Delivering affordable localization technology to our physicians and developing additional solutions.”
Sjoerd van Gorp, senior investment manager at BOM Brabant Ventures, says the investment was made because of opportunities to provide optimum care to patients with breast cancer. “The innovative solution developed by Sirius will lead to a better care process. This is crucial in today’s healthcare.”
Sirius Pintuition enables breast surgeons to accurately pinpoint the tumor location during surgery while optimizing hospital workflow. Sirius Pintuition provides surgical oncologists with a high precision solution that contributes to an improved hospital workflow. The Sirius Pintuition System is CE marked and FDA clearance is pending. The Sirius Pintuition seed can be placed up to 180 days before the surgery to mark a target within soft tissue. During surgery, the Sirius Pintuition Probe provides highly accurate, real-time feedback and directional guidance to the marked tissue.
Sirius Medical originated in the Antoni van Leeuwenhoek Hospital and the University of Twente with the aim of improving oncological surgery. The company is located at the High Tech Campus Eindhoven.